Table 2.
Comparison of baseline serum cytokine concentrations (pg/ml) in 931 samples, by oral HPV statusa
| Median serum concentration at baseline (IQR) | ||||
|---|---|---|---|---|
| Cytokine | No Oral HPV n=311 |
Incident Oral HPV n=313 |
Prevalent Oral HPV n=307 |
p-trend |
| TNF-α | 3.1 (2.4-4.3) | 3.3 (2.5-4.5) | 3.5 (2.6-4.8) | 0.009 |
| IL-6 | 1.0 (0.7-1.8) | 1.1 (0.7-1.7) | 1.1 (0.7-1.7) | 0.41 |
| IL-8 | 15.2 (10.7-38.1) | 16.4 (11.4-37.5) | 19.5 (13.0-62.3) | 0.001 |
| IFN-γ | 8.0 (5.2-14.1) | 8.2 (5.4-15.7) | 9.4 (5.7-16.5) | 0.03 |
| IL-10 | 0.47 (0.27-0.76) | 0.55 (0.32-0.89) | 0.60 (0.37-0.94) | 0.001 |
| IL-2 | 0.27 (0-0.55) | 0.34 (0-0.55) | 0.38 (0-0.59) | 0.007 |
a
For samples with no oral HPV or prevalent HPV, baseline was defined as POPS enrollment. For samples with incident HPV, baseline was defined as visit of incident HPV detection. Unadjusted (no log transformation) median cytokine concentrations and interquartile ranges (IQR, 25th to 75th percentiles, in parentheses) are shown. Bolding indicates values with p<0.05 in tests for trend. Results were similar when restricted to only HIV-infected, or only HIV-uninfected participants (results not shown).